| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early March 2024. |
| Process | STA Standard |
| ID number | 5094 |
Provisional Schedule
| Expected publication | 20 November 2024 |
Project Team
| Project lead | Celia Mayers |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
| External Assessment Group | Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors | Merck Sharp & Dohme |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Aspire Pharma (pemetrexed) – confidentiality agreement not signed, not participating |
| AstraZeneca (durvalumab, osimertinib) | |
| Bristol Myers Squibb (nivolumab, paclitaxel) | |
| Dr Reddy’s Laboratories (pemetrexed) – confidentiality agreement not signed, not participating | |
| Eli Lilly (pemetrexed) – confidentiality agreement not signed, not participating | |
| Genus Pharmaceuticals (pemetrexed) – confidentiality agreement not signed, not participating | |
| Medac (oxaliplatin) – confidentiality agreement not signed, not participating | |
| Pfizer (cisplatin, carboplatin, docetaxel oxaliplatin, paclitaxel, pemetrexed) – confidentiality agreement not signed, not participating | |
| Roche (atezolizumab) | |
| Sandoz (cisplatin, pemetrexed) – confidentiality agreement not signed, not participating | |
| Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) – confidentiality agreement not signed, not participating | |
| Sun Pharmaceuticals (oxaliplatin) – confidentiality agreement not signed, not participating | |
| Teva UK (paclitaxel) – confidentiality agreement not signed, not participating | |
| Zentiva (pemetrexed) – confidentiality agreement not signed, not participating | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 October 2024 - 30 October 2024 | Final draft guidance |
| 18 September 2024 | NICE has agreed to pause publication of the guidance document to allow the company and NHS England to enter into a commercial discussion. Once these discussions have concluded, NICE will update stakeholders with the next steps. We expect this to be late September or early October 2024. |
| 07 August 2024 | Committee meeting |
| 07 August 2024 | Declaration of interests |
| 09 January 2024 | Invitation to participate |
| 13 November 2023 - 27 November 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5094 |
| 13 November 2023 | In progress. Commenced to scoping |
| 30 March 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer have been revised. It is anticipated that the appraisal will begin in early-January 2024 when we will write to you about how you can get involved. |
| 07 July 2022 | Awaiting development. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual